Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Charles Herbaux, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Mayerhöfer ME, Poulain S, Tournilhac O, Pemovska T, Chong SJF, Van der Kouwe E, Kazianka L, Hopfinger G, Heintel D, Jäger R, Raderer M, Jäger U, Simonitsch-Klupp I, Sperr WR, Kubicek S, Davids MS, Staber PB. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021 Aug 01; 106(8):2251-2256. PMID: 33626863.
    Citations:    Fields:    
  2. Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 Jun 24; 137(25):3495-3506. PMID: 33598678.
    Citations: 1     Fields:    
  3. Tomowiak C, Poulain S, Herbaux C, Perrot A, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Nollet D, Roos-Weil D, Chevret S, Leblond V. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Adv. 2021 05 11; 5(9):2438-2446. PMID: 33961019.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  4. Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, Bodet-Milin C, Ragot S, Bossard C, Nadal N, Herbaux C, Tessoulin B, Tchernonog E, Rossi C, McCulloch R, Gastinne T, Callanan MB, Rule S. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021 02 18; 137(7):877-887. PMID: 33181832.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  5. Demonchy J, Cordier C, Fréalle E, Demarquette H, Herbaux C, Escure G, Willaume A, Van De Wyngaert Z, Noel MP, Facon T, Faure K, Caro J, Morgan G, Davies FE, Alfandari S, Bories C, Boyle EM. Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Jun; 21(6):e545-e547. PMID: 33642203.
    Citations:    Fields:    
  6. Bouclet F, Calleja A, Dilhuydy MS, Véronèse L, Pereira B, Amorim S, Cymbalista F, Herbaux C, de Guibert S, Roos-Weil D, Hivert B, Aurran T, Dupuis J, Blouet A, Tchernonog E, Laribi K, Dmytruck N, Morel P, Michallet AS, Dartigeas C, Tournilhac O, Nguyen-Khac F, Delmer A, Feugier P, Ysebaert L, Guièze R. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Ann Hematol. 2021 Apr; 100(4):987-993. PMID: 33495922.
    Citations:    Fields:    Translation:Humans
  7. Chong SJF, Iskandar K, Lai JXH, Qu J, Raman D, Valentin R, Herbaux C, Collins M, Low ICC, Loh T, Davids M, Pervaiz S. Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 12 16; 48(22):12727-12745. PMID: 33245769.
    Citations: 2     Fields:    Translation:HumansCells
  8. Manson G, Brice P, Herbaux C, Bouabdallah K, Antier C, Poizeau F, Dercle L, Houot R. Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation. Haematologica. 2020 11 01; 105(11):2664-2666. PMID: 33131257.
    Citations: 1     Fields:    Translation:Humans
  9. Beauvais D, Herbaux C. Should I Allograft a Patient with Hodgkin Lymphoma Who Is Responding to Nivolumab? Biol Blood Marrow Transplant. 2020 08; 26(8):e175-e176. PMID: 32302753.
    Citations:    Fields:    Translation:Humans
  10. Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, Karlin L, Dyer MJS, Mitra SS, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jürgensmeier JM, Fegan CD. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 06 15; 26(12):2810-2818. PMID: 32156743.
    Citations: 10     Fields:    
  11. Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot JM, Cullières-Dartigues P, Suttle B, Karlin L, Le Gouill S, Picquenot JM, Dubois R, Tilly H, Herbaux C, Jardin F, Salles G, Ribrag V. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Clin Cancer Res. 2020 07 01; 26(13):3145-3153. PMID: 32122924.
    Citations: 9     Fields:    
  12. Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 05; 95(5):510-520. PMID: 32052473.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  13. Delaby G, Hubaut MA, Morschhauser F, Besson A, Huglo D, Herbaux C, Baillet C. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline 18F-FDG PET-CT. Leuk Lymphoma. 2020 07; 61(7):1584-1591. PMID: 32100597.
    Citations: 1     Fields:    Translation:Humans
  14. Manson G, Brice P, Herbaux C, Bouabdallah K, Antier C, Poizeau F, Dercle L, Houot R. Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation. Haematologica. 2020 Feb 13. PMID: 32054648.
    Citations:    Fields:    
  15. Van de Wyngaert Z, Carpentier B, Pascal L, Lionne-Huyghe P, Leduc I, Srour M, Vasseur M, Demarquette H, Terriou L, Herbaux C, Manier S, Bossard JB, Barbieux S, Chauvet P, Willaume A, Nudel M, Bories C, Gibier JB, Facon T, Boyle EM. Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. Br J Haematol. 2020 02; 188(3):e24-e27. PMID: 31742668.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  16. Senouci A, Smol T, Tricot S, Bakala J, Moulessehoul S, Quilichini B, Penther D, Herbaux C, Daudignon A. Cytogenetic landscape in 1012 newly diagnosed chronic lymphocytic leukemia. Eur J Haematol. 2019 Dec; 103(6):607-613. PMID: 31512291.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  17. Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial. Br J Haematol. 2019 11; 187(3):319-327. PMID: 31218679.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  18. Renaud L, Schraen S, Fouquet G, Guidez S, Demarquette H, Nudel M, Cayssials E, Bories C, Herbaux C, Systchenko T, Faucompré JL, Machet A, Sabirou F, Levy A, Bobin A, Richez V, Moya N, Gruchet C, Desmier D, van de Wyngaert Z, Carpentier B, Manier S, Facon T, Harding S, Leleu X. Response to pneumococcal vaccination in multiple myeloma. Cancer Med. 2019 07; 8(8):3822-3830. PMID: 31145552.
    Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
  19. Nudel M, Baran-Marszak F, Bossard JB, Dubois R, Dapvril H, Dupuis J, Laribi K, Bay JO, Tomowiak C, Dreyfus B, Lepretre S, Demarquette H, Wallyn F, Wemeau L, Wemeau M, Poulain S, Morschhauser F, Cymbalista F, Herbaux C. Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the FILO group. Br J Haematol. 2019 09; 186(5):e126-e130. PMID: 31115898.
    Citations:    Fields:    Translation:Humans
  20. Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, Bouabdallah K, Moles-Moreau MP, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Chauchet A, Damotte D, Dercle L, Brice P, Houot R. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019 07; 115:47-56. PMID: 31082693.
    Citations: 7     Fields:    Translation:Humans
  21. Herbaux C, Davids MS. Venetoclax: R-CHOP rocket booster? Blood. 2019 05 02; 133(18):1922-1924. PMID: 31048302.
    Citations:    Fields:    Translation:Humans
  22. Sarkozy C, Copie-Bergman C, Damotte D, Ben-Neriah S, Burroni B, Cornillon J, Lemal R, Golfier C, Fabiani B, Chassagne-Clément C, Parrens M, Herbaux C, Xerri L, Bossard C, Laurent C, Cheminant M, Cartron G, Cabecadas J, Molina T, Salles G, Steidl C, Ghesquières H, Mottok A, Traverse-Glehen A. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA. Am J Surg Pathol. 2019 03; 43(3):341-351. PMID: 30540571.
    Citations: 8     Fields:    Translation:Humans
  23. Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019 07; 186(1):146-149. PMID: 30548257.
    Citations: 5     Fields:    Translation:Humans
  24. Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019 Jan; 6(1):e48-e57. PMID: 30528137.
    Citations: 34     Fields:    Translation:Humans
  25. Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Am J Hematol. 2018 Jun 08. PMID: 29884994.
    Citations: 24     Fields:    
  26. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Jun 21; 378(25):2399-2410. PMID: 29856685.
    Citations: 53     Fields:    Translation:HumansCTClinical Trials
  27. Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano JM, Ghesquieres H, Dercle L, Houot R. Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood. 2018 06 21; 131(25):2856-2859. PMID: 29724901.
    Citations: 8     Fields:    Translation:Humans
  28. Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018 07 05; 132(1):9-16. PMID: 29720488.
    Citations: 28     Fields:    Translation:Humans
  29. Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursière E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub-Agha I, Bouabdallah K, Durot E, Damaj G. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol. 2018 Jun; 93(6):729-735. PMID: 29473209.
    Citations: 2     Fields:    Translation:Humans
  30. Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018 04 26; 131(17):1955-1959. PMID: 29437588.
    Citations: 71     Fields:    Translation:HumansCTClinical Trials
  31. Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). Am J Hematol. 2018 02; 93(2):E52-E54. PMID: 29164674.
    Citations: 1     Fields:    Translation:Humans
  32. Bertrand E, Jouy N, Manier S, Fouquet G, Guidez S, Boyle E, Noel S, Tomowiak C, Herbaux C, Schraen S, Preudhomme C, Quesnel B, Poulain S, Leleu X. Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström's macroglobulinemia. Oncotarget. 2017 Dec 22; 8(68):112917-112927. PMID: 29348877.
    Citations: 1     Fields:    
  33. Guillermin Y, Herbaux C, Subtil F, Aurran-Schleinitz T, Cymbalista F, Letestu R, Leprêtre S, Vaudaux S, Laribi K, Leblond V, Defoi Y, Benchikh R, Salles G, Godmer P, Jardel H, Vallais F, Feugier P, Orsini F, Pegourié B, Lévy V, Michallet AS. Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group. Am J Hematol. 2018 01; 93(1):E24-E27. PMID: 29055105.
    Citations:    Fields:    Translation:Humans
  34. Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, Geffroy S, Sebda S, Nibourel O, Nudel M, Herbaux C, Renaud L, Tomowiak C, Guidez S, Tricot S, Roche-Lestienne C, Quesnel B, Preudhomme C, Leleu X. TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clin Cancer Res. 2017 Oct 15; 23(20):6325-6335. PMID: 28754818.
    Citations: 17     Fields:    Translation:HumansCells
  35. Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJS. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. Blood. 2017 05 18; 129(20):2808-2810. PMID: 28377400.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  36. Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017 05 04; 129(18):2471-2478. PMID: 28270452.
    Citations: 70     Fields:    Translation:HumansCTClinical Trials
  37. Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget. 2016 Dec 20; 7(51):85573-85583. PMID: 27458168.
    Citations: 1     Fields:    Translation:Humans
  38. Herbaux C, Bertrand E, Marot G, Roumier C, Poret N, Soenen V, Nibourel O, Roche-Lestienne C, Broucqsault N, Galiègue-Zouitina S, Boyle EM, Fouquet G, Renneville A, Tricot S, Morschhauser F, Preudhomme C, Quesnel B, Poulain S, Leleu X. BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia. Oncotarget. 2017 Aug 22; 8(34):57451-57459. PMID: 28924457.
    Citations: 1     Fields:    
  39. Pascart T, Herbaux C, Lemaire A, Soncin F, Hachulla E, Hatron PY, Terriou L. Coexistence of rheumatoid arthritis and TEMPI syndrome: New insight in microangiogenic-related diseases. Joint Bone Spine. 2016 Oct; 83(5):587-8. PMID: 26639219.
    Citations:    Fields:    Translation:Humans
  40. Poulain S, Roumier C, Venet-Caillault A, Figeac M, Herbaux C, Marot G, Doye E, Bertrand E, Geffroy S, Lepretre F, Nibourel O, Decambron A, Boyle EM, Renneville A, Tricot S, Daudignon A, Quesnel B, Duthilleul P, Preudhomme C, Leleu X. Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia. Clin Cancer Res. 2016 Mar 15; 22(6):1480-8. PMID: 26490317.
    Citations: 26     Fields:    Translation:HumansCells
  41. Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, Salles G, Leblond V, Leleu X. Lenalidomide is safe and active in Waldenström macroglobulinemia. Am J Hematol. 2015 Nov; 90(11):1055-9. PMID: 26284823.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  42. Herbaux C, Duployez N, Badens C, Poret N, Gardin C, Decamp M, Eclache V, Daliphard S, Murati A, Cony-Makhoul P, Cheze S, Beve B, Lacoste C, Prebet T, Hunault-Berger M, Maloisel F, Renneville A, Figeac M, Stamatoullas-Bastard A, Bastard C, Fenaux P, Preudhomme C, Rose C. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis. Am J Hematol. 2015 Aug; 90(8):737-8. PMID: 26017030.
    Citations: 2     Fields:    Translation:HumansCells
  43. Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S, Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L. Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol. 2015 Mar; 168(6):916-9. PMID: 25316212.
    Citations: 13     Fields:    Translation:Humans
  44. Fouquet G, Bories C, Guidez S, Renaud L, Herbaux C, Javed S, Facon T, Leleu X. Pomalidomide for multiple myeloma. Expert Rev Hematol. 2014 Dec; 7(6):719-31. PMID: 25265911.
    Citations: 3     Fields:    Translation:Humans
  45. Poulain S, Boyle EM, Roumier C, Demarquette H, Wemeau M, Geffroy S, Herbaux C, Bertrand E, Hivert B, Terriou L, Verrier A, Pollet JP, Maurage CA, Onraed B, Morschhauser F, Quesnel B, Duthilleul P, Preudhomme C, Leleu X. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol. 2014 Nov; 167(4):506-13. PMID: 25160558.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  46. Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, Onraed B, Faucompré JL, Hennache B, Petillon MO, Mathiot C, Avet-Loiseau H, Facon T, Harding SJ, Moreau P, Leleu X. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. Cancer. 2014 Dec 15; 120(24):3952-7. PMID: 25116271.
    Citations: 6     Fields:    Translation:Humans
  47. Fouquet G, Guidez S, Herbaux C, Van de Wyngaert Z, Bonnet S, Beauvais D, Demarquette H, Adib S, Hivert B, Wemeau M, Berthon C, Terriou L, Coiteux V, Macro M, Decaux O, Facon T, Huglo D, Leleu X. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014 Jun 15; 20(12):3254-60. PMID: 24714772.
    Citations: 16     Fields:    Translation:Humans
  48. Poulain S, Roumier C, Galiègue-Zouitina S, Daudignon A, Herbaux C, Aiijou R, Lainelle A, Broucqsault N, Bertrand E, Manier S, Renneville A, Soenen V, Tricot S, Roche-Lestienne C, Duthilleul P, Preudhomme C, Quesnel B, Morel P, Leleu X. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. Am J Hematol. 2013 Nov; 88(11):948-54. PMID: 23861223.
    Citations: 10     Fields:    Translation:HumansCells
  49. Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T, Hulin C, Leleu X. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer. 2013 Oct 15; 119(20):3680-6. PMID: 23921945.
    Citations: 8     Fields:    Translation:Humans
  50. Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, Tricot S, Daudignon A, Galiègue-Zouitina S, Soenen V, Theisen O, Grardel N, Nibourel O, Roche-Lestienne C, Quesnel B, Duthilleul P, Preudhomme C, Leleu X. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013 May 30; 121(22):4504-11. PMID: 23532735.
    Citations: 54     Fields:    Translation:HumansCells
  51. Poulain S, Herbaux C, Bertrand E, Decambron A, Fouquet G, Boyle E, Gay J, Manier S, Duthilleul P, Roumier C, Leleu X. Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):202-4. PMID: 23473949.
    Citations: 4     Fields:    Translation:Humans
  52. Herbaux C, Badens C, Guidez S, Lacoste C, Maboudou P, Rose C. A new ATRX mutation in a patient with acquired a-thalassemia myelodysplastic syndrome. Hemoglobin. 2012; 36(6):581-5. PMID: 23092150.
    Citations:    Fields:    Translation:HumansCells
  53. Mareville J, Gay J, Cliquennois E, Herbaux C, Pasquier F, Allorge D, Blondiaux N, Berthon C, Alfandari S. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients. Scand J Infect Dis. 2012 May; 44(5):398-401. PMID: 22235869.
    Citations:    Fields:    Translation:Humans
  54. Herbaux C, Poulain S, Meyer C, Marschalek R, Renneville A, Fernandes J, Theisen O, Tricot S, Simon M, Duthilleul P, Daudignon A. TOP3A, a new partner gene fused to MLL in an adult patient with de novo acute myeloid leukaemia. Br J Haematol. 2012 Apr; 157(1):128-31. PMID: 22050635.
    Citations: 1     Fields:    Translation:HumansCells
  55. Rose C, Fournier M, Nibourel O, Herbaux C, Charpentier A, Renneville A, Pissard S, Badens C, Preudhomme C. Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy. Leuk Res. 2011 Nov; 35(11):e203-5. PMID: 21831427.
    Citations: 1     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Herbaux's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (215)
Co-Authors (8)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.